142 related articles for article (PubMed ID: 21062242)
21. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
22. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
23. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
[TBL] [Abstract][Full Text] [Related]
24. MPN blast phase: clinical challenge and assessing response.
Mesa RA; Tibes R
Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
[No Abstract] [Full Text] [Related]
25. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
26. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
27. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Tefferi A
Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
[TBL] [Abstract][Full Text] [Related]
28. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
[TBL] [Abstract][Full Text] [Related]
29. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
30. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
31. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
[TBL] [Abstract][Full Text] [Related]
33. The spectrum of JAK2-positive myeloproliferative neoplasms.
Kiladjian JJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():561-6. PubMed ID: 23233635
[TBL] [Abstract][Full Text] [Related]
34. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
Robinson SE; Harrison CN
Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
[TBL] [Abstract][Full Text] [Related]
35. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
36. New advances in the pathogenesis and therapy of essential thrombocythemia.
Levine RL; Heaney M
Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
[TBL] [Abstract][Full Text] [Related]
37. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
38. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
Liu L; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
